[QT Interval in Patients With COVID-19].

Komoliatova, V N; Makarov, L M

Komoliatova, V N; Makarov, L M.

Afiliación

Komoliatova VN; Center for syncope and cardiac arrhythmias in children and adolescents of the FMBA of Russia. FGBUZ Central Children's Clinical Hospital FMBA of Russia. Department of Pediatrics named after G.N. Speransky RMANPO Ministry of Health of the Russian Federation.
Makarov LM; Center for syncope and cardiac arrhythmias in children and adolescents of the FMBA of Russia. FGBUZ Central Children's Clinical Hospital FMBA of Russia. Department of Pediatrics named after G.N. Speransky RMANPO Ministry of Health of the Russian Federation.

Kardiologiia ; 60(7): 11-14, 2020 Aug 11.

Article en Ru | MEDLINE | ID: mdl-33155935

RESUMEN

Since the first case recorded in the end of 2019, the virus SARS-CÐ¾V-2 and the related lung disease COVID-19 have spread over the world and became a threat for public health. The drugs used for treatment of this disease (azithromycin and hydroxychloroquine) can prolong the QT interval on the electrocardiogram to increase the risk of pirouette tachycardia and sudden cardiac death. This article presents a review of potential risks related with the drug treatment of COVID-19 and provides recommendations for management of patients during the pandemic.

Asunto(s)

Betacoronavirus; Infecciones por Coronavirus; Síndrome de QT Prolongado; Pandemias; Neumonía Viral; COVID-19; Humanos; Síndrome de QT Prolongado/epidemiología; SARS-CoV-2

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neumonía Viral / Síndrome de QT Prolongado / Infecciones por Coronavirus / Pandemias / Betacoronavirus Tipo de estudio: Guideline Límite: Humans Idioma: Ru Revista: Kardiologiia Año: 2020 Tipo del documento: Article Pais de publicación: Rusia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google